Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Approves Incyte’s Pemazyre, Bayer’s Vitrakvi, Novartis’ Kesimpta, and More
March 24, 2021
- Incidence of Post-Vaccine Anaphylaxis in Japan Comparable with US: MHLW
March 23, 2021
- Appraisal Results for Kymriah, Trelegy Up for Chuikyo Review on March 24; Price Cuts Likely
March 23, 2021
- COVID-19 Vaccines to Be Shipped with 6-Dose Syringes from Week of April 12, for Use in 2nd-in-Line HCPs
March 23, 2021
- Govt Disclosing Suspected Vaccine Reactions Less Frequently after Expert Advice: Minister
March 22, 2021
- MHLW Panel Hails Use of Clinical Research Data for Regulatory Submissions, but Wants Requirements to Ensure Safety
March 22, 2021
- MHLW to Set Up Medical Supply Office in April after COVID-19, Antibiotic Shortage
March 19, 2021
- Japan to Boost Screening of Coronavirus Variants: Minister
March 19, 2021
- Japan IP High Court Snubs Ex-Grad Student's Appeal over Opdivo Patent Claim
March 19, 2021
- Monitoring Panel to Require MHLW's Periodic Reports on Products Designated for Sakigake Review, Conditional Early Approval
March 18, 2021
- MHLW to Continue Looking into Cause of Generic Scandals: Minister
March 17, 2021
- All Municipalities to Get 2nd Doses for HCPs by Week of May 10: Minister
March 15, 2021
- No Significant Concerns Observed with Pfizer COVID-19 Vaccine: Japan Safety Panels
March 15, 2021
- Site Pain Common with COVID-19 Vaccine, but It Improves in 3 Days: Safety Follow-Up
March 15, 2021
- MHLW Don’t Rule Out 7 Doses per Vial, but Won’t Recommend It for Pfizer Vaccine: Minister
March 15, 2021
- MHLW Panel Determines Medical Need for 4 Drugs Including Acetaminophen
March 15, 2021
- Olumiant, 7 More APIs Earn Orphan Designation: MHLW
March 12, 2021
- 2nd-Dose Shot Starts for COVID-19 Vaccination in Japan
March 12, 2021
- AMED to Fund 22 More Projects to Develop COVID-19 Treatments
March 11, 2021
- Govt Won’t Widely Recommend Use of 7-Dose Syringes for Pfizer Vaccine: Top Spokesman
March 10, 2021
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…